ReviewMolecular diversity2026
Medicinal chemistry perspective of chalcone derivatives as anticancer agents: synthetic strategy, biological activity, and structure-activity relationship.
Review in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Chalcone andMolecules (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chalcones are a subclass of flavonoids characterized by the presence of an α, β-unsaturated carbonyl system, and they have emerged as important scaffolds in medicinal chemistry because of their structural simplicity, ease of synthesis, and wide spectrum of pharmacological activities. They occur abundantly in nature and are reported to exhibit antioxidant, anti-inflammatory, antimicrobial, and particularly anticancer effects, making them attractive leads for therapeutic development. This review specifically highlights the most recent advances in chalcone-based anticancer research, with a focus on the structural features directly linked to enhanced cytotoxicity activity. Naturally occurring chalcones and their general pharmacological significance are briefly summarized to provide fundamental context. Classical methods, such as the Claisen-Schmidt condensation, remain the most widely used due to their simplicity and high yields, while modern catalytic, solvent-free, and green methodologies have expanded the diversity and efficiency of chalcone libraries. In parallel, structure-activity relationship (SAR) analyses are highlighted to illustrate how substituent effects, heterocyclic incorporation, and linker modifications influence activity profiles. Selected studies are discussed to demonstrate the relationship between structural design and cytotoxic responses across different cancer models. In the selected studies, aim to demonstrate how structural modifications can modulate cellular interactions, enhance therapeutic efficacy, and impact treatment outcomes across various cancer models. By integrating advances in synthesis with biological evaluation, this review emphasizes the versatility of chalcones and provides an updated framework for guiding rational design. The collective evidence underscores their promise as adaptable scaffolds for the development of next-generation anticancer agents.
Indexed as
Identifiers
41739383What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.